Table 4 Frequency of patients with at least one emergent adverse event (occurring in ≥5 % of patients): safety population
|  | Chondroitin sulfate (n = 97) | Celecoxib (n = 97) | p valuea | ||
|---|---|---|---|---|---|
Events | n (%) | Events | n (%) | ||
Musculoskeletal and connective tissue disorders | 72 | 37 (38.1) | 59 | 38 (39.2) | >0.999 |
 Arthralgia | 19 | 14 (14.4) | 14 | 11 (11.3) | 0.669 |
 Back pain | 17 | 16 (16.5) | 5 | 5 (5.2) | 0.019 |
 Pain in extremity | 6 | 3 (3.1) | 8 | 7 (7.2) | 0.331 |
Infections and infestations | 66 | 34 (35.1) | 61 | 32 (33.0) | 0.880 |
 Nasopharyngitis | 28 | 19 (19.6) | 18 | 15 (15.5) | 0.572 |
Gastrointestinal disorders | 37 | 27 (27.8) | 44 | 29 (29.9) | 0.874 |
 Dyspepsia | 12 | 12 (12.4) | 12 | 12 (12.4) | 1.000 |
 Gastroesophageal reflux disease | 5 | 5 (5.2) | 5 | 5 (5.2) | 1.000 |
Nervous system disorders | 21 | 16 (16.5) | 22 | 21 (21.6) | 0.465 |
 Headache | 15 | 12 (12.4) | 10 | 10 (10.3) | 0.821 |
Respiratory, thoracic, and mediastinal disorders | 19 | 15 (15.5) | 20 | 14 (14.4) | >0.999 |
 Sinusitis | 5 | 5 (5.2) | 6 | 6 (6.2) | >0.999 |
Injury, poisoning, and procedural complications | 18 | 14 (14.4) | 18 | 13 (13.4) | >0.999 |
General disorders and administration site conditions | 12 | 11 (11.3) | 12 | 11 (11.3) | 1.000 |
Skin and subcutaneous tissue disorders | 3 | 3 (3.1) | 11 | 11 (11.3) | 0.049 |
Psychiatric disorders | 4 | 4 (4.1) | 9 | 9 (9.3) | 0.250 |
Investigations | 6 | 6 (6.2) | 6 | 6 (6.2) | 1.000 |
Surgical and medical procedures | 8 | 5 (5.2) | 8 | 6 (6.2) | >0.999 |
Vascular disordersb | 7 | 6 (6.2) | 5 | 4 (4.1) | 0.747 |